Daniel G. Bracewell is Professor of Bioprocess Analysis at the UCL Department of Biochemical Engineering. He has made major contributions to the fundamental understanding of biopharmaceutical purification operations, generating over £5.5 million in research funds including new international research collaborations with India and the USA. He has authored more than 90 peer reviewed journal articles in the area to date and currently supervises 15 doctoral and postdoctoral projects, many of these studies are in collaboration with industry. One such project became the technology basis from which the spinout Puridify (recently acquired by GE Healthcare) developed.